Health Insurer Financial Performance in 2024

This analysis of trends in health insurers’ financial data shows that insurers’ gross margins per enrollee dipped slightly in 2024 across four markets, remaining highest in the Medicare Advantage market, followed by the individual (non-group) market, the fully insured group (employer) market, and Medicaid managed care. The analysis also examines insurers’ medical-loss ratios across the…

Read More

New KFF Tracking Poll on Health Information and Trust Finds One in Three Adults Have Used AI Chatbots for Health Advice — The Monitor

KFF’s latest Tracking Poll finds that one-third of the public report using AI chatbots for health information and advice in the past year. And a federal judge suspended, for now, the appointments of thirteen members of ACIP, halting a scheduled meeting and staying recent, widely debated, changes to the childhood vaccine schedule.

Read More

GVX Venture Studio Launches FusionCare.AI: A One-Stop Shop for Obesity Care at the Future and Health Executive Summit at JPM 2025

Combining AI-driven insights with tailored care pathways, patients gain access to health coaches, psychologists, and treatment plans, while providers benefit from workflow optimization. The post GVX Venture Studio Launches FusionCare.AI: A One-Stop Shop for Obesity Care at the Future and Health Executive Summit at JPM 2025 appeared first on MedCity News.

Read More

How AI is Unlocking Smarter Clinical Trial Protocols

By fine-tuning domain-specific models with real clinical operations data — such as historical performance, feasibility outcomes, enrollment patterns, and resource utilization — hidden information can be translated into structured intelligence. The post How AI is Unlocking Smarter Clinical Trial Protocols appeared first on MedCity News.

Read More

FDA Rejection Delays Regeneron From Competing With J&J, Pfizer in Multiple Myeloma

Regeneron Pharmaceuticals said the FDA cited no approvability concerns for its multiple myeloma drug, linvoseltamab, other than previously identified issues with a contract manufacturer. While linvoseltamab trails bispecific antibodies currently marketed by Johnson & Johnson and Pfizer, if approved, it could bring patients an earlier treatment option. The post FDA Rejection Delays Regeneron From Competing…

Read More